靶向p300/CBP轴治疗致死性前列腺癌
本文验证靶向p300/CBP是致死性前列腺癌的治疗策略,并描述新型小分子抑制剂CCS1477靶向p300/CBP保守溴结构域。CCS1477抑制前列腺癌细胞系增殖、降低AR与C-MYC调控基因表达,在AR剪接变体驱动模型中具抗肿瘤活性;早期临床研究提示其可调节KLK3血水平和CRPC活检生物标志物表达。
要点
- CCS1477抑制p300/CBP溴结构域,降低AR与C-MYC调控基因表达。
- 在AR剪接变体驱动模型中CCS1477显示抗肿瘤活性。
- 早期临床提示CCS1477可调节KLK3血水平及CRPC活检标志物。
核心结论
- 靶向p300/CBP是致死性前列腺癌的可行治疗策略,CCS1477在晚期前列腺癌治疗中显示前景。
研究设计与样本
- 临床前研究结合早期临床研究,验证p300/CBP靶点并描述小分子抑制剂CCS1477。
- 在前列腺癌细胞系及AR剪接变体驱动模型中进行评价。
- 早期临床研究评估CCS1477对KLK3血水平和CRPC活检生物标志物的影响。
主要发现
- CCS1477抑制前列腺癌细胞系增殖。
- CCS1477降低AR和C-MYC调控的基因表达。
- 在AR-SV驱动模型中CCS1477具有抗肿瘤活性并调节AR与C-MYC信号。
- 早期临床研究提示CCS1477调节KLK3血水平和CRPC活检生物标志物表达。
临床怎么用
- 对AR阻断耐药的CRPC可考虑靶向p300/CBP的转录辅激活因子抑制策略。
- CCS1477的临床获益尚需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer (CRPC) is associated with sustained AR signaling, including through alternative splicing of AR (AR-SV). Inhibitors of transcriptional coactivators that regulate AR activity, including the paralog histone acetyltransferase proteins p300 and CBP, are attractive therapeutic targets for lethal prostate cancer. Herein, we validate targeting p300/CBP as a therapeutic strategy for lethal prostate cancer and describe CCS1477, a novel small-molecule inhibitor of the p300/CBP conserved bromodomain. We show that CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases AR- and C-MYC-regulated gene expression. In AR-SV-driven models, CCS1477 has antitumor activity, regulating AR and C-MYC signaling. Early clinical studies suggest that CCS1477 modulates KLK3 blood levels and regulates CRPC biopsy biomarker expression. Overall, CCS1477 shows promise for the treatment of patients with advanced prostate cancer. SIGNIFICANCE: Treating CRPC remains challenging due to persistent AR signaling. Inhibiting transcriptional AR coactivators is an attractive therapeutic strategy. CCS1477, an inhibitor of p300/CBP, inhibits growth and AR activity in CRPC models, and can affect metastatic CRPC target expression in serial clinical biopsies.See related commentary by Rasool et al., p. 1011.This article is highlighted in the In This Issue feature, p. 995.
引用
- Welti J, Sharp A, Brooks N, et al. Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021. PMID: 33431496. doi:10.1158/2159-8290.CD-20-0751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。